A Real World Study of Apatinib in Treatment of Patients With Gastric Carcinoma

• Conditions: Gastric Carcinoma

• Registration Number: NCT03735511
• Lead Sponsor: Henan Cancer Hospital

Brief Summary

The study was designed to evaluate the efficacy and safety of apatinib in the treatment of patients with gastric carcinoma.

Detailed Description

The study is a real-world non-interventional retrospective study and will collect the original medical records of patients with gastric carcinoma treated with apatinib from 2015 to 2018 in Henan Cancer Hospital. Clinical data such as patient demographic, history of treatments, tumor biological characteristics and adverse events will be analyzed to evaluate the efficacy and safety of apatinib and explore the risk factors of prognosis in patients with gastric carcinoma.

Study Timeline

• Study First Submitted: 2018-11-07
• Study First Submitted QC: 2018-11-07
• Study First Posted: 2018-11-08
• Study Start: 2018-11-20
• Status Verified: 2020-04
• Last Update Submitted: 2020-04-23
• Last Update Posted: 2020-04-27
• Primary Completion: 2020-08
• Study Completion: 2020-08

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 270

Inclusion Criteria

1. Pathologically or cytologically confirmed gastric or residual gastric or gastroesophageal junction carcinoma;
2. Patients received apatinib treatment at least once.

Exclusion Criteria

1. No specific exclusion criteria in this real world study.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Overall Survival	2015-2018	Overall Survival

Secondary Outcome Measures

Name	Time	Method
Objective Response Rate	2015-2018	Objective Response Rate
Disease Control Rate	2015-2018	Disease Control Rate
Progression-Free Survival	2015-2018	Progression-Free Survival

Trial Locations

Locations (1)

Henan Cancer Hospital; 🇨🇳 Zhengzhou, Henan, China